These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30356037)

  • 1. Liver stiffness-based model for portal hypertension and hepatocellular cancer risk in HBV responsive to antivirals.
    Marzano A; Tucci A; Chialà C; Saracco GM; Fadda M; Debernardi Venon W
    Minerva Gastroenterol Dietol; 2019 Mar; 65(1):11-19. PubMed ID: 30356037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis.
    Shin SH; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
    Liver Int; 2015 Mar; 35(3):1054-62. PubMed ID: 24930484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
    Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
    Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model.
    Kim BK; Kim DY; Han KH; Park JY; Kim JK; Paik YH; Lee KS; Chon CY; Ahn SH
    Am J Gastroenterol; 2011 Sep; 106(9):1654-62, 1730. PubMed ID: 21691339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy.
    Song BG; Sinn DH; Chi S; Kim K; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1447-1452. PubMed ID: 30063482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy.
    Shim JJ; Oh CH; Kim JW; Lee CK; Kim BH
    Scand J Gastroenterol; 2017 Sep; 52(9):1029-1036. PubMed ID: 28562104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.
    Berzigotti A; Seijo S; Arena U; Abraldes JG; Vizzutti F; García-Pagán JC; Pinzani M; Bosch J
    Gastroenterology; 2013 Jan; 144(1):102-111.e1. PubMed ID: 23058320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis.
    Lin CW; Lin CC; Mo LR; Chang CY; Perng DS; Hsu CC; Lo GH; Chen YS; Yen YC; Hu JT; Yu ML; Lee PH; Lin JT; Yang SS
    J Hepatol; 2013 Apr; 58(4):730-5. PubMed ID: 23220252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
    Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
    J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
    Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spleen stiffness in patients with cirrhosis in predicting esophageal varices.
    Sharma P; Kirnake V; Tyagi P; Bansal N; Singla V; Kumar A; Arora A
    Am J Gastroenterol; 2013 Jul; 108(7):1101-7. PubMed ID: 23629600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
    Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
    Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.
    Oh JH; Lee HW; Sinn DH; Park JY; Kim BK; Kim SU; Kim DY; Ahn SH; Kang W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Paik YH
    Hepatol Int; 2021 Aug; 15(4):892-900. PubMed ID: 34260013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.
    Su TH; Peng CY; Tseng TC; Yang HC; Liu CJ; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2020 Feb; 221(4):589-597. PubMed ID: 31574141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
    Thabut D; Bureau C; Layese R; Bourcier V; Hammouche M; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle-Bladou C; Dao T; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Hillaire S; Di Martino V; Sutton A; Audureau E; Roudot-Thoraval F; Nahon P;
    Gastroenterology; 2019 Mar; 156(4):997-1009.e5. PubMed ID: 30768988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.